Dupixent Wrongful Death Lawsuit Filed Over T-Cell Lymphoma Diagnosis

Woman received first Dupixent injections in June 2024, and died of T-cell lymphoma complications in late October 2024.

The daughter of a Tennessee woman is pursuing a wrongful death lawsuit, after her mother died of T-cell lymphoma from Dupixent, which was allegedly caused or exacerbated by side effects of the popular inflammatory treatment.

The complaint (PDF) was filed this week by Chandra Richardson, on behalf of herself and her deceased mother, Cynthia Marie Hyde, naming Regeneron Pharmaceuticals and Sanofi-Aventis U.S. Inc. as the defendants.

Dupixent (dupilumab) was approved in 2017 as a treatment for asthma and various inflammatory disease that affect the skin and respiratory tract. The medication is given by injection every two to four weeks, and has quickly become a blockbuster treatment in the United States.

However, over the past year, concerns have emerged about a link between side effects of Dupixent and T-cell lymphoma, a rare form of cancer that affects white blood cells. Specifically, Dupixent has been linked to increased risks of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL), the latter of which the lawsuit claims caused Hyde’s death.

As a result of these findings, it is expected that Richardson’s lawsuit is one of the first of a series of Dupixent lawsuits that will be brought on behalf of individuals diagnosed with T-cell lymphoma after receiving the injections.

According to the lawsuit, Hyde was diagnosed with adult-onset atopic dermatitis in 2019 and prescribed Dupixent in May 2024, after other treatments failed. She began receiving injections in June and July, and instead of relief, her condition worsened.

The complaint indicates Hyde developed raised, thickened scars on her forehead and arm, along with darkened, swollen patches that spread across most of her body, including her face, arms, legs and torso. The injections were discontinued after these reactions, although her symptoms continued to escalate.

By September 2024, a biopsy revealed Hyde had peripheral T-cell lymphoma (PTCL), an aggressive and often fatal cancer. The lawsuit suggests Dupixent may have triggered previously dormant cutaneous T-cell lymphoma (CTCL), accelerating the disease and leading to her rapid decline. After weeks of intense pain and suffering, Hyde died on October 28, 2024.

Her family accuses Regeneron and Sanofi-Aventis, the makers of Dupixent, of knowing about the risks of lymphoma while failing to warn patients or doctors, allegedly prioritizing profits over patient safety.

“Defendants failed to warn, instruct, advise, educate, or otherwise inform Dupixent users and prescribers, including Decedent and Decedent’s treating physicians, about the risk of development and/or exacerbation of CTCL and PTCL. The U.S. label for Dupixent makes no mention of these risks.”

– Cynthia Richardson, et al. v. Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC.

Richardson presents claims of failure to warn, negligence, negligent misrepresentation, breach of warranty, wrongful death and survival action.

Dupixent T-Cell Lymphoma Lawsuits

Law firms are now investigating Dupixent cancer lawsuits like Richardson’s for individuals who were prescribed the drug for any of its approved uses and later diagnosed with cutaneous T-cell lymphoma (CTCL) or another T-cell lymphoma subtype.

To receive a free consultation to determine if you or a loved one may be eligible to file a lawsuit, submit information for review by a Dupixent lawyer.